A multinational, randomized, phase III trial of XELIRI ( plus bevacizumab) versus FOLFIRI ( plus bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).

被引：0
|
作者：
Muro, Kei
Kim, Tae Won
Park, Young Suk
Uetake, Hiroyuki
Nishina, Tomohiro
Nozawa, Hiroaki
Matsumoto, Hiroshi
Yamazaki, Kentaro
Han, Sae-Won
Lee, Keun-Wook
Deng, Yanhong
Buyse, Marc E.
Satoh, Taroh
Ryoo, Baek-Yeol
Shen, Lin
Iwasa, Satoru
Morita, Satoshi
Sakamoto, Junichi
Xu, Rui-hua
机构：
[1] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea
[4] Tokyo Med & Dent Univ, Dept Surg Specialties, Tokyo, Japan
[5] Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[6] Univ Tokyo, Dept Surg Oncol, Tokyo, Japan
[7] Tokyo Metropolitan Komagome Hosp, Tokyo, Japan
[8] Shizuoka Canc Ctr, Shizuoka, Japan
[9] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul Natl Univ Hosp,Canc Res Inst, Seoul 151, South Korea
[10] Seoul Natl Univ, Coll Med, Bundang Hosp, Seoul, South Korea
[11] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China
[12] Int Inst Drug Dev, Cambridge, MA USA
[13] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Osaka, Japan
[14] Beijing Canc Hosp, Beijing, Peoples R China
[15] Natl Canc Ctr, Gastrointestinal Med Oncol Div, 1-1 Tsukiji 5 chome, Tokyo, Japan
[16] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[17] Tokai Cent Hosp, Kakamigahara, Japan
[18] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.tps780
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS780
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
    Gorbunova, Vera
    Beck, J. Thaddeus
    Hofheinz, Ralf-Dieter
    Garcia-Alfonso, Pilar
    Nechaeva, Marina
    Gracian, Antonio Cubillo
    Mangel, Laszlo
    Fernandez, Elena Elez
    Deming, Dustin A.
    Ramanathan, Ramesh K.
    Torres, Alison H.
    Sullivan, Danielle
    Luo, Yan
    Berlin, Jordan D.
    BRITISH JOURNAL OF CANCER, 2019, 120 (02) : 183 - 189
  • [22] A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
    Vera Gorbunova
    J. Thaddeus Beck
    Ralf-Dieter Hofheinz
    Pilar Garcia-Alfonso
    Marina Nechaeva
    Antonio Cubillo Gracian
    Laszlo Mangel
    Elena Elez Fernandez
    Dustin A. Deming
    Ramesh K. Ramanathan
    Alison H. Torres
    Danielle Sullivan
    Yan Luo
    Jordan D. Berlin
    British Journal of Cancer, 2019, 120 : 183 - 189
  • [23] Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.
    Gorbunova, Vera
    Beck, Thaddeus
    Hofheinz, Ralf
    Garcia-Alfonso, Pilar
    Nechaeva, Marina
    Gracian, Antonio Cubillo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] XELIRI compared with FOLFIRI as a second-line treatment in patients with. metastatic colorectal cancer
    Cui, Chengxu
    Shu, Chang
    Yang, Yi
    Liu, Junbao
    Shi, Shuping
    Shao, Zhujun
    Wang, Nan
    Yang, Ting
    Hu, Songnian
    ONCOLOGY LETTERS, 2014, 8 (04) : 1864 - 1872
  • [25] Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for metastatic colorectal cancer patients.
    Matsubara, Yuki
    Masuishi, Toshiki
    Ogata, Takatsugu
    Nakazawa, Taiko
    Kato, Kyoko
    Nozawa, Kazuki
    Narita, Yukiya
    Honda, Kazunori
    Bando, Hideaki
    Kadowaki, Shigenori
    Ando, Masashi
    Tajika, Masahiro
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [26] A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer
    Jo, H.
    Lee, M-S
    Lee, Y-P
    Kim, H.
    Hong, J. Y.
    Lee, J.
    Park, S. H.
    Park, J. O.
    Park, Y. S.
    Lim, H. Y.
    Kang, W. K.
    Kim, S. T.
    CLINICAL ONCOLOGY, 2022, 34 (08) : E323 - E328
  • [27] FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma
    Guion-Dusserre, Jean-Florian
    Lorgis, Veronique
    Vincent, Julie
    Bengrine, Leila
    Ghiringhelli, Francois
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (07) : 2096 - 2101
  • [28] FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma
    Jean-Florian Guion-Dusserre
    Veronique Lorgis
    Julie Vincent
    Leila Bengrine
    Francois Ghiringhelli
    World Journal of Gastroenterology, 2015, (07) : 2096 - 2101
  • [29] Impact of omitting fluorouracil from FOLFIRI plus bevacizumab in second-line treatment of metastatic colorectal cancer
    Matsubara, Yuki
    Masuishi, Toshiki
    Ogata, Takatsugu
    Nakazawa, Taiko
    Kato, Kyoko
    Nozawa, Kazuki
    Narita, Yukiya
    Honda, Kazunori
    Bando, Hideaki
    Kadowaki, Shigenori
    Ando, Masashi
    Tajika, Masahiro
    Muro, Kei
    ANNALS OF ONCOLOGY, 2021, 32 : S321 - S321
  • [30] Randomized phase 2 study of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus FOLFIRI/FOLFOX and bevacizumab as second-line treatment of advanced colorectal cancer (DeFianCe).
    Wainberg, Zev A.
    Boccia, Ralph V.
    Strickler, John H.
    Moehler, Markus H.
    Sirard, Cynthia A.
    Walsh, Erin K.
    Parker, Elizabeth C.
    Lee, Keun-Wook
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS275 - TPS275
12345